Evgen Pharma PLC AGM Statement (8391V)
July 26 2018 - 1:02AM
UK Regulatory
TIDMEVG
RNS Number : 8391V
Evgen Pharma PLC
26 July 2018
For immediate release 26 July 2018
Evgen Pharma plc
("Evgen" or "the Company")
AGM Statement
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, will hold its Annual General Meeting ("AGM") later
today in Manchester. At the AGM, the Company's Chairman, Barry
Clare, will make the following statement:
"The current financial year has seen major progress with SFX-01,
our lead product candidate, which continues to progress through two
Phase II trials in metastatic breast cancer and subarachnoid
haemorrhage, a type of stroke.
"The final read-out from both trials continues to be expected at
around the end of this calendar year, marking important value
inflexion points in the clinical development of SFX-01.
"We have already announced highly encouraging data from the
metastatic breast cancer trial in an interim update in June 2018,
which revealed SFX-01's signs of anti-tumour activity in a patient
group where other treatment options had failed.
"Furthermore, yesterday we announced that the main aims of the
metastatic breast cancer trial had been achieved, namely a
favourable safety profile and evidence of clinical benefit, and
that recruitment into the trial had been concluded at 50 patients
rather than the total of 60 allowed under the trial protocol. We
await the final details of the read-out of the trial with
excitement, and see the likely next step for SFX-01 in metastatic
breast cancer as a placebo-controlled trial with SFX-01 in
combination with second-line hormone therapy in patients who have
failed on CDK4/6 inhibitors.
"Patient recruitment continues on track in the subarachnoid
haemorrhage trial with all three sites recruiting, including the
most recent site addition, St Bartholomew's Hospital, London.
"We look forward to providing further updates on both the
clinical and corporate development of the Company during the months
ahead."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
Dr Stephen Franklin, CEO 7466 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly +44 (0) 20 7466
Abraham 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry
Beaney (Corporate Finance) +44 (0) 20 3861
Rob Rees (Corporate Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMEASXKAAPPEEF
(END) Dow Jones Newswires
July 26, 2018 02:02 ET (06:02 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024